KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Interest Coverage Ratio (2016 - 2025)

Historic Interest Coverage Ratio for Halozyme Therapeutics (HALO) over the last 13 years, with Q3 2025 value amounting to 50.73.

  • Halozyme Therapeutics' Interest Coverage Ratio rose 4061.94% to 50.73 in Q3 2025 from the same period last year, while for Sep 2025 it was 41.53, marking a year-over-year increase of 6346.87%. This contributed to the annual value of 30.48 for FY2024, which is 6938.59% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Interest Coverage Ratio stood at 50.73 for Q3 2025, which was up 4061.94% from 46.07 recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Interest Coverage Ratio high stood at 53.11 for Q2 2021, and its period low was 10.97 during Q2 2022.
  • For the 5-year period, Halozyme Therapeutics' Interest Coverage Ratio averaged around 29.09, with its median value being 25.91 (2024).
  • In the last 5 years, Halozyme Therapeutics' Interest Coverage Ratio surged by 438426.38% in 2021 and then plummeted by 7933.88% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Interest Coverage Ratio stood at 27.51 in 2021, then tumbled by 40.74% to 16.3 in 2022, then increased by 18.72% to 19.36 in 2023, then soared by 99.72% to 38.66 in 2024, then skyrocketed by 31.22% to 50.73 in 2025.
  • Its Interest Coverage Ratio was 50.73 in Q3 2025, compared to 46.07 in Q2 2025 and 31.28 in Q1 2025.